

## SenzaGen receives SEK 0.5 million order from world-leading ingredient and raw material supplier

SenzaGen will assess the skin sensitizing hazards of chemicals for a global company specialized in ingredients and raw materials for several different industries and markets. The new order, with a value of approximately SEK 0.5 million, includes testing with both GARD™skin and GARD™potency. The unique ability of the GARD technology to both assess “difficult-to-test” chemicals and determine whether a substance is a weak or strong allergen (potency), was crucial for the agreement. The tests will be carried out at SenzaGen's laboratory in Lund.

With a business operating globally, the customer is headquartered in Europe where innovation, research and development have a central role. The collaboration between the two companies started in the beginning of 2020. After a successful completion of the first tests, the collaboration continues with the signing of the new order.

“I am extremely happy about this collaboration. The new order confirms that our work in our prioritized market segments generates results and that our tests meet the needs of the largest and leading players in the market. Once again, the interest in GARD’s unique ability to test “difficult-to-test” chemicals and their potency is confirmed”, says Axel Sjöblad, CEO of SenzaGen.

### For more information, please contact:

Axel Sjöblad, CEO, SenzaGen AB

Email: [axel.sjoblad@senzagen.com](mailto:axel.sjoblad@senzagen.com) | Mobile: +46 705-35 93 51

Tina Dackemark Lawesson, VP Marketing & Communications

Email: [tina.lawesson@senzagen.com](mailto:tina.lawesson@senzagen.com) | Mobile: +46 708 20 29 44

### About GARD

GARD consists of a group of tests for analyzing chemicals’ ability to start an allergic reaction in humans. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence and targets companies looking to optimize their *in vitro* testing strategy; increasing the accuracy of their test results while avoiding animal testing. Through its precision and reliability, GARD improves the quality of customers’ decision-making and contributes to increased product safety in people’s everyday lives while reducing the number of animal experiments. SenzaGen is the only company that can offer a non-animal, so called *in vitro* test, for chemical respiratory allergens. The product portfolio consists of tests for skin and respiratory allergy: GARD™skin, GARD™air, GARD™potency and GARD™skin Medical Device.

### About SenzaGen AB (publ)

SenzaGen’s technology enables replacement of animal experiments with genetic testing in test tubes for determining the allergenicity of the chemicals we come into contact with in our daily lives, such as



Lund, May 19, 2020

those in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. SenzaGen sells direct and through partners. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in the US. For more information, please visit [www.senzagen.com](http://www.senzagen.com).

SenzaGen AB is listed on Nasdaq First North in Stockholm (ticker: SENZA) and FNCA Sweden AB, +46(0)8-528 00 399 [info@fnca.se](mailto:info@fnca.se), is the company's Certified Adviser.